Obesity and cancer risk

Does Obesity Cause Cancer? What Your Metabolic Numbers Add

Yes, for a growing list of cancers: higher BMI is tied to greater risk of 19 cancer types, and the risk travels through what excess fat does to blood sugar, insulin and inflammation.

About four in ten US cancers trace to factors people can change, and excess weight ranks second. The deeper driver is metabolic, and most of it goes unmeasured at a routine visit.

Does obesity cause cancer? For a growing list of cancers the evidence now says it does, and the number on the scale is the least interesting part of the answer: the risk travels through what excess fat does to blood sugar, insulin and inflammation, the metabolic damage a routine checkup rarely measures.

How much cancer is tied to things that can change

American Cancer Society researchers estimated that in 2019, 40.0% of new cancers in US adults aged 30 and older, 713,340 of 1,781,649 cases outside common skin cancers, and 44.0% of cancer deaths, 262,120 of 595,737, were attributable to risk factors that can potentially be changed. Cigarette smoking led, at 19.3% of cases and 28.5% of deaths. Excess body weight came second, at 7.6% of cases and 7.3% of deaths, ahead of alcohol at 5.4% and 4.1%.

Treat that 7.6% as a floor for metabolic harm, not a ceiling. The analysis counted excess body weight. High blood sugar, insulin resistance and metabolic syndrome were not on its list of evaluated risk factors, so a person of ordinary weight whose metabolism is failing added nothing to that share. The headline undercounts exactly the person a scale reassures, and the metabolic part of the story has to be read from other studies.

The list of weight-linked cancers keeps growing

In 2024, two cancer epidemiologists writing in The Lancet Regional Health – Europe asked the question directly: is obesity a cause of all cancer types? A 2026 systematic review in Nature Metabolism, with one of those two on its author team, gave the most complete answer so far. It pooled 226 articles covering 1.5 million cancer diagnoses from prospective studies of 25 cancer types and found higher BMI tied to greater risk of 19 cancers and lower risk of 3. Leukemia, non-Hodgkin lymphoma, bladder cancer and glioma were added compared with earlier consensus reports. Waist circumference behaved much like BMI, and genetic studies were generally consistent with the observational findings. Not every cancer, then, but far more than most people assume. Liver cancer is on that list, and the first warning is often a scarring score most patients never see, explained in what a fibrosis score says about a fatty liver.

Metabolic syndrome carries its own risk

Metabolic syndrome is a cluster of findings: a large waist, high blood pressure, high blood sugar, high triglycerides and low HDL cholesterol. A 2024 meta-analysis of 31 prospective cohort studies linked it to higher risk of five digestive cancers: colorectal (relative risk 1.13), esophageal (1.17), pancreatic (1.25), gallbladder (1.37) and liver (1.46). Stomach cancer was the exception. Among combinations of those findings, obesity with high blood pressure and high blood sugar had the strongest link to colorectal cancer, 1.54 in men and 1.27 in women. Genetic studies within the same paper, a way of separating cause from coincidence, supported waist-to-hip ratio, BMI and HbA1c, the three-month blood sugar average, as causes of colorectal cancer.

This evidence is observational and genetic, not randomized, because nobody can assign people to decades of high insulin and wait for tumors; that is exactly why the mechanism carries weight. Why would metabolism feed a tumor? A 2026 review published alongside the meta-analysis names three routes: sex hormones, hyperinsulinemia and chronic inflammation. Insulin is a growth signal. When cells resist it, the pancreas pushes out more, and every tissue that listens to insulin keeps hearing an instruction to grow. Inflamed fat tissue adds a steady stream of alarm chemicals, the metaflammation that keeps repair switched on long after anything needs repairing. Two biological engines, then, and one fuel line. The third driver sits outside the body. A food supply engineered around acellular carbohydrates and industrial seed oils, much of it grown from subsidized commodity crops, keeps both engines fed meal after meal, and then the same system treats the tumor as bad luck.

Colorectal cancer is arriving younger

Colorectal cancer in adults under 50 has been rising since the 1990s, and a 2025 review in Nature Reviews Endocrinology described it as an emerging disease of metabolic dysregulation, climbing alongside obesity and type 2 diabetes in young people. In a 2026 meta-analysis of eleven cohort studies, overweight or obesity carried 1.59 times the odds of early-onset colorectal cancer, and obesity alone 1.81. Among 357 Australian adults referred for colonoscopy, where waist and weight told part of the story, 41.7% had metabolic syndrome, and in those over 40 with a BMI of 25 or more, the adjusted odds were 2.26 for any polyp and 2.64 for an adenoma, the type of polyp that can turn into cancer.

Weight is not the whole explanation, and that matters for anyone who is not heavy. Australian modeling published in 2026 estimated that obesity in adolescence accounts for a growing but small share of early-onset colorectal cancers, rising from 2% to 6% in men, and judged it unlikely to be the main driver of the rise. Read beside the metabolic syndrome findings, that points past the scale toward blood sugar, insulin and inflammation. If you are young, of ordinary weight and told your risk is low because you are not heavy, that reassurance rests on the wrong number. The same trap catches the normal-BMI South Asian or East Asian adult who is skinny fat, thin outside and metabolically inflamed and insulin resistant inside.

Risk is not fixed at the weight you once were

In a population cohort of 800,024 people whose BMI was measured at pre-military evaluations in late adolescence and again in adulthood, those who went from a normal weight to a high one had 1.31 times the risk of obesity-related cancers, and those who stayed heavy had 1.47 times. People who were heavy as teenagers but reached a normal adult weight showed no clear excess, with a hazard ratio of 1.01. Each 5% of weight gained raised the hazard by 3%, and the same held for cancers diagnosed before 50. The trajectory, not the starting point, carried the risk, and a trajectory is something you can track and still change.

Metabolic health, meanwhile, has become the exception. Fewer than 12.2% of US adults qualified as optimally metabolically healthy in NHANES data from 2009 through 2016, and once stricter criteria arrived after 2021 the share fell below 7%. A normal weight does not settle the question. Unmeasured is unmanaged. For older adults with high blood pressure, a waist measure adjusted for weight has been tested against stroke, as covered in waist index screening for stroke.

What a checkup covers, and what measurement adds

Cancer screening itself, such as colonoscopy and mammography, is ordered by your physician and done elsewhere. A standard checkup records weight and blood pressure and usually checks glucose, A1c and cholesterol. What it tends to leave out is fasting insulin, which climbs for years while glucose still looks normal, and any measure of how much of your weight is fat and how much is muscle.

Measura [Cardiometabolic and Autonomic Health Analysis] measures; it does not screen for cancer, diagnose it or treat it, and results go to your physician.

Laboratory panels can add fasting insulin, C-peptide and high-sensitivity C-reactive protein to glucose, A1c and lipids, putting insulin resistance and inflammation on paper. The pattern is described in what insulin resistance looks like before diabetes.
Bioimpedance body composition estimates how much of your weight is fat and how much is muscle, which BMI cannot do. It estimates compartments rather than imaging them, so it cannot map the fat packed around your organs the way a scan can; why that deep fat matters is covered in visceral fat vs subcutaneous fat.

Questions worth bringing to your next visit: Am I due for colorectal cancer screening, given my age and family history? What is my fasting insulin, as a number? Do I meet the definition of metabolic syndrome? More prompts are in questions worth asking your doctor, and the background is in insulin resistance and metabolic health.

Frequently asked questions

Does obesity cause cancer, or is it only linked to it?

For many cancers the evidence points toward cause. In a 2026 review of prospective studies, higher BMI was tied to 19 cancers, and genetic studies were generally consistent with those findings, which argues against coincidence. Excess fat acts through insulin, inflammation and hormones, so the metabolic picture matters as much as the scale. Where that fat sits is explained in how to measure visceral fat.

Can my cancer risk be raised at a normal weight?

Metabolic syndrome carried its own link to colorectal, liver and pancreatic cancer, and its parts, such as high blood sugar, high triglycerides and low HDL cholesterol, can appear at an ordinary weight. Weight alone does not rule out the metabolic side. What a normal A1c can hide is explained in fasting insulin test: what a normal A1c can hide.

Does losing weight lower cancer risk?

Trials that follow weight loss all the way to cancer diagnoses are rare, because cancer takes years to appear. In a large cohort, people who were heavy as teenagers but reached a normal adult weight showed no clear excess risk, while each 5% of weight gained raised risk by 3%. Keeping lost weight from returning is covered in how to maintain weight loss.

Can Measura test me for cancer?

Measura does not screen for, diagnose or treat cancer. Colonoscopy, mammography and other cancer screening are ordered by your physician and done elsewhere. Measura measures the metabolic terrain, including insulin, inflammation and body composition, and sends those results to your physician. How those numbers can be tracked as they change is described in how to lower insulin resistance.

Why is colorectal cancer rising in younger adults?

Nobody has a complete answer yet. Overweight and obesity raise the odds of colorectal cancer before 50, but modeling suggests adolescent obesity explains only a small share of the rise, so researchers are looking at metabolic dysregulation, diet and early-life exposures together. One piece of that terrain is discussed in does sugar cause inflammation.

Measure the metabolic side of your risk

Ask to have your fasting insulin, inflammation markers and body composition measured, so your physician can see the metabolic terrain that weight alone does not show.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Islami, F., Marlow, E. C., Thomson, B., McCullough, M. L., Rumgay, H., Gapstur, S. M., Patel, A. V., Soerjomataram, I., & Jemal, A. (2024). Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA: A Cancer Journal for Clinicians, 74(5), 405-432. https://doi.org/10.3322/caac.21858
Gunter, M. J., & Berrington de Gonzalez, A. (2024). Is obesity a cause of all cancer types? The Lancet Regional Health – Europe, 46, 101110. https://doi.org/10.1016/j.lanepe.2024.101110
Watts, E. L., Gonzalez-Feliciano, A., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2026). Adiposity and cancer: systematic review and meta-analysis. Nature Metabolism, 8(6), 1426-1439. https://doi.org/10.1038/s42255-026-01542-8
Watts, E. L., Gonzalez-Feliciano, A., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2026). Adiposity and cancer: epidemiology, mechanisms and future perspectives. Nature Metabolism, 8(6), 1266-1281. https://doi.org/10.1038/s42255-026-01529-5
Zhan, Z. Q., Chen, Y. Z., Huang, Z. M., Luo, Y. H., Zeng, J. J., Wang, Y., Tan, J., Chen, Y. X., & Fang, J. Y. (2024). Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta-analysis of 31 prospective cohorts and Mendelian randomization study. Journal of Gastroenterology and Hepatology, 39(4), 630-641. https://doi.org/10.1111/jgh.16477
Du, M., Drew, D. A., Goncalves, M. D., Cao, Y., & Chan, A. T. (2025). Early-onset colorectal cancer as an emerging disease of metabolic dysregulation. Nature Reviews Endocrinology, 21(11), 686-702. https://doi.org/10.1038/s41574-025-01159-z
Wang, H., Wu, C., Zhou, S., Shi, Y., Cheng, L., Cao, H., Zhang, Y., & Gao, S. (2026). Body mass index and early-onset colorectal cancer risk: a systematic review and cohort-based meta-analysis. Scandinavian Journal of Gastroenterology, 61(4), 383-396. https://doi.org/10.1080/00365521.2026.2615397
Kumar, R., Brown, A., Okano, S., Simms, L., Lord, A., O’Sullivan, T., Hartel, G., & Radford-Smith, G. L. (2024). Overweight and obesity are associated with colorectal neoplasia in an Australian outpatient population. Scientific Reports, 14(1), 23501. https://doi.org/10.1038/s41598-024-74042-y
Min, J., Jenkins, M. A., & Meyers, A. L. (2026). Early-onset colorectal cancer burden attributable to early-life obesity from 2000 to 2020 with projections to 2040. Cancer Epidemiology, 105, 103219. https://doi.org/10.1016/j.canep.2026.103219
Bendor, C. D., Bardugo, A., Tsur, A. M., Derazne, E., Shemesh, I. I., Bourvine, L., et al. (2026). Adolescent to adulthood weight trajectories and the risk of obesity-related cancers, overall and early-onset: a population-based cohort study. EClinicalMedicine, 91, 103711. https://doi.org/10.1016/j.eclinm.2025.103711